Senate Finance Committee Turns Attention To Pfizer COX-2 Documents
The Senate Finance Committee is starting to review Pfizer documents on COX-2 inhibitors submitted in response to a December request
The Senate Finance Committee is starting to review Pfizer documents on COX-2 inhibitors submitted in response to a December request